Milestone Pharmaceuticals (NASDAQ:MIST) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Posted by Stuart Ham on Mar 13th, 2025

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) released its earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.04), Zacks reports.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST opened at $1.93 on Thursday. The company has a market cap of $102.92 million, a price-to-earnings ratio of -2.38 and a beta of 1.83. Milestone Pharmaceuticals has a 1 year low of $1.12 and a 1 year high of $2.75. The stock’s 50 day simple moving average is $2.02 and its two-hundred day simple moving average is $1.79. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a research note on Friday, February 28th.

Check Out Our Latest Stock Report on Milestone Pharmaceuticals

About Milestone Pharmaceuticals

(Get Free Report)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.